Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 3/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363833 | 1.00 | CD38 (0.54) | CD38HPGDSIRAK4EGFRTP53 | |
| SCHEMBL6368111 | 1.00 | CD38 (0.54) | CD38HPGDSIRAK4EGFRTP53 | |
| SCHEMBL6363717 | 0.86 | CD38 (0.56) | CD38IRAK4 | |
| SCHEMBL8308249 | 0.86 | CD38 (0.56) | CD38IRAK4 | |
| SCHEMBL6363714 | 0.86 | CD38 (0.56) | CD38IRAK4 | |
| SCHEMBL6364052 | 0.85 | IRAK4 (0.47) | IRAK4EGFR | |
| SCHEMBL6363835 | 0.83 | IRAK4 (0.49) | IRAK4EGFR | |
| SCHEMBL21369343 | 0.79 | IRAK4 (0.65) | CD38IRAK4EGFRTP53 | |
| SCHEMBL6368146 | 0.79 | GRM1 (0.55) | IRAK4EGFR | |
| SCHEMBL22368021 | 0.78 | IRAK4 (0.65) | CD38HPGDSIRAK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038047-A1 | Azaquinazoline derivatives | AZI2, P2RX5, P2RX7 | CD38 1418/4885HPGDS 167/4885IRAK4 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.